Characterization of regulatory T cells in SARS-CoV-2 infected hemodialysis patients: relation to clinical and radiological severity

[1]  G. Deferrari,et al.  The role of kidney dysfunction in COVID-19 and the influence of age , 2022, Scientific Reports.

[2]  T. Pieber,et al.  Chronic Inflammation Might Protect Hemodialysis Patients From Severe COVID-19 , 2022, Frontiers in Immunology.

[3]  F. Budak,et al.  Assessment of CD39 expression in regulatory T‐cell subsets by disease severity in adult and juvenile COVID‐19 cases , 2022, Journal of medical virology.

[4]  B. Walker,et al.  Profound Treg perturbations correlate with COVID-19 severity , 2021, Proceedings of the National Academy of Sciences.

[5]  Md. Sahidul Islam,et al.  The role of CD4+FoxP3+ regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment , 2021, International journal of biological sciences.

[6]  D. Weiner,et al.  COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider , 2021, American Journal of Kidney Diseases.

[7]  Gabriel Ștefan,et al.  Clinical features and outcome of maintenance hemodialysis patients with COVID-19 from a tertiary nephrology care center in Romania , 2020, Renal failure.

[8]  L. Gesualdo,et al.  SARS-CoV-2 and Viral Sepsis: Immune Dysfunction and Implications in Kidney Failure , 2020, Journal of clinical medicine.

[9]  Z. Memish,et al.  Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID‐19 plus acute kidney injury: A case‐series , 2020, Artificial organs.

[10]  G. Matarese,et al.  T Cells: Warriors of SARS-CoV-2 Infection , 2020, Trends in Immunology.

[11]  Lyanne M. Kieneker,et al.  COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  A. Sette,et al.  Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19 , 2020, Cell.

[13]  C. Wanner,et al.  Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe , 2020, Kidney International.

[14]  Xiaowen Jiang,et al.  Characteristics of immune cells and cytokines in patients with coronavirus disease 2019 in Guangzhou, China , 2020, Human Immunology.

[15]  L. Roshangar,et al.  Th17 and Treg cells function in SARS‐CoV2 patients compared with healthy controls , 2020, Journal of cellular physiology.

[16]  M. O'gorman,et al.  Lymphocyte Subset Counts in COVID‐19 Patients: A Meta‐Analysis , 2020, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[17]  C. Roca,et al.  An open resource for T cell phenotype changes in COVID-19 identifies IL-10-producing regulatory T cells as characteristic of severe cases , 2020, medRxiv.

[18]  J. Xiang,et al.  Impaired T cell functions along with elevated activated Tregs at the early stage of asymptomatic SARS-CoV-2 infection , 2020, medRxiv.

[19]  Chengliang Zhu,et al.  Decreased T cell populations contribute to the increased severity of COVID-19 , 2020, Clinica Chimica Acta.

[20]  Hui Tang,et al.  Clinical Characteristics of and Medical Interventions for COVID-19 in Hemodialysis Patients in Wuhan, China. , 2020, Journal of the American Society of Nephrology : JASN.

[21]  Jian-Ping Liu,et al.  The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients , 2020, International Immunopharmacology.

[22]  Ruoqing Li,et al.  Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan, China , 2020, Journal of Clinical Virology.

[23]  Zixi Hong,et al.  COVID-19 in Hemodialysis Patients: A Report of 5 Cases , 2020, American Journal of Kidney Diseases.

[24]  Kunwei Li,et al.  CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19) , 2020, European Radiology.

[25]  Hong Jiang,et al.  Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up , 2020, Journal of Infection.

[26]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[27]  A. Davenport,et al.  Immune response to influenza vaccination in ESRD patients undergoing hemodialysis vs. hemodiafiltration , 2020, PloS one.

[28]  Qin Ning,et al.  Clinical and immunological features of severe and moderate coronavirus disease 2019 , 2020 .

[29]  L. Uhlmann,et al.  End‐stage renal disease, dialysis, kidney transplantation and their impact on CD4+ T‐cell differentiation , 2018, Immunology.

[30]  Yan Kang,et al.  What Else Can CD39 Tell Us? , 2017, Front. Immunol..

[31]  J. Eliaou,et al.  ENTPD1/CD39 is a promising therapeutic target in oncology , 2013, Oncogene.

[32]  W. Weimar,et al.  Uremia causes premature ageing of the T cell compartment in end-stage renal disease patients , 2012, Immunity & Ageing.

[33]  M. Betjes,et al.  Premature aging of circulating T cells in patients with end-stage renal disease. , 2011, Kidney international.

[34]  R. Medzhitov,et al.  Not so fast: adaptive suppression of innate immunity , 2007, Nature Medicine.

[35]  Y. Wan,et al.  Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression , 2007, Nature.

[36]  B. Jaber,et al.  Pulmonary infectious mortality among patients with end-stage renal disease. , 2001, Chest.